Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mimedx (MDXG) Capital Expenditures (2016 - 2026)

Mimedx's Capital Expenditures history spans 16 years, with the latest figure at $570000.0 for Q1 2026.

On a quarterly basis, Capital Expenditures rose 51.19% to $570000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $1.2 million, a 33.84% increase, with the full-year FY2025 number at $1.0 million, down 38.62% from a year prior.
Capital Expenditures hit $570000.0 in Q1 2026 for Mimedx, up from $285000.0 in the prior quarter.
Over the last five years, Capital Expenditures for MDXG hit a ceiling of $2.0 million in Q4 2023 and a floor of -$932000.0 in Q3 2023.
Historically, Capital Expenditures has averaged $399235.3 across 5 years, with a median of $299000.0 in 2023.
The widest YoY moves for Capital Expenditures: up 436.44% in 2023, down 367.05% in 2023.
Tracing MDXG's Capital Expenditures over 5 years: stood at $667000.0 in 2022, then skyrocketed by 197.9% to $2.0 million in 2023, then tumbled by 86.76% to $263000.0 in 2024, then grew by 8.37% to $285000.0 in 2025, then skyrocketed by 100.0% to $570000.0 in 2026.
Business Quant data shows Capital Expenditures for MDXG at $570000.0 in Q1 2026, $285000.0 in Q4 2025, and $192000.0 in Q3 2025.